医学
内科学
内分泌学
肾
药理学
贫血
酶
化学
肾病
泌尿系统
摘要
Renal anemia is a major complication of kidney disease due to defects in the renal production of erythroid growth factor erythropoietin (EPO). A new class of agents for the treatment of anemia that activate hypoxia-inducible transcription factors (HIFs) by inhibiting HIF-prolyl hydroxylases (HIF-PHs, also known as PHDs) and induce EPO production in the kidney and liver was launched in 2019. Currently, a variety of HIF-PH inhibitors (HIF-PHIs) are clinically available. Although many studies, including ours, have investigated the effects and pharmacokinetics of each HIF-PHI in animal models, the differences among HIF-PHIs remain to be clarified. To provide information on the drug-specific features of HIF-PHIs for their clinical use, this study compared them using mice. The data demonstrated that the pharmacokinetics of 5 HIF-PHIs (daprodustat, enarodustat, molidustat, roxadustat, and vadadustat) in plasma and urine are different, whereas they are commonly cleared from the body within 3 days after administration. Additionally, we discovered that HIF-PHIs alter the expression levels of the Epo gene and other HIF target genes related to iron metabolism in a drug-specific manner. These findings are helpful in considering the clinical use of HIF-PHIs to treat renal anemia as well as in establishing the detection methods of the drugs in anti-doping tests.
科研通智能强力驱动
Strongly Powered by AbleSci AI